Values as of: 2024-10-30
COMMON STOCK | Biotechnology |
Last Closing
USD 25.13Change
-0.58 (-2.26)%Market Cap
USD 3.62BVolume
2.39MAnalyst Target
USD 39.50Verdict
Verdict
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Company Website : https://www.tgtherapeutics.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+4.72 (+1.00%) |
USD 121.32B |
| REGN | Regeneron Pharmaceuticals Inc |
-4.54 (-0.49%) |
USD 103.77B |
| ALNY | Alnylam Pharmaceuticals Inc |
-3.20 (-1.12%) |
USD 36.83B |
| ARGX | argenx NV ADR |
-1.17 (-0.21%) |
USD 33.21B |
| BGNE | BeiGene Ltd |
-10.54 (-4.87%) |
USD 24.57B |
| MRNA | Moderna Inc |
-0.50 (-0.91%) |
USD 20.52B |
| RPRX | Royalty Pharma Plc |
+0.04 (+0.15%) |
USD 16.47B |
| UTHR | United Therapeutics Corporatio.. |
+8.60 (+2.44%) |
USD 15.69B |
| SMMT | Summit Therapeutics PLC |
-3.18 (-14.57%) |
USD 15.13B |
| PCVX | Vaxcyte Inc |
+0.55 (+0.52%) |
USD 13.95B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| BBP | Virtus LifeSci Biotech Pr.. | 2.11 % | 0.79 % |
-0.56 (0.96%) |
USD 0.02B |
| PBE | Invesco Dynamic Biotechno.. | 0.00 % | 0.57 % |
+0.66 (+0.96%) |
N/A |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 47.13% | 54% | F | 76% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 47.13% | 54% | F | 76% | C+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 148.32% | 62% | D | 81% | B- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 148.32% | 62% | D | 81% | B- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 254.94% | 72% | C | 86% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 254.94% | 72% | C | 86% | B+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 68.81% | 82% | B | 91% | A- | ||
| Dividend Return | 68.81% | 82% | B | 91% | A- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 154.41% | 27% | F | 14% | F | ||
| Risk Adjusted Return | 44.56% | 92% | A | 74% | C | ||
| Market Capitalization | 3.62B | 93% | A | 86% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company had negative total cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
